Latest Conference Articles

Consistency among caregivers can be an important factor for patients undergoing treatment for cancer.

Several drugs are in the pipeline for the treatment of specialty conditions, including cancer and multiple sclerosis.

The fate of the 340B program is unclear amid several proposals to make changes.

Women in Specialty Pharmacy Lunch brings together leaders from various aspects of the specialty landscape.

Payer requirements for outcomes data are becoming more stringent.

Testing and treatment programs should focus on populations driving new cases of hepatitis C virus.

Outcomes and accreditation measures are among the key factors in building a successful specialty pharmacy, according to a session at the annual NASP meeting.

Rebecca Shanahan, NASP president and CEO of Avella Specialty Pharmacy, announced the Distinguished Service Award and the Specialty Pharmacy of the Year Award.

Certified specialty pharmacists have greater opportunities and credibility in the growing market, according to a session at the annual NASP meeting.

Direct and indirect remuneration fees have inflicted harm on specialty pharmacies and the patients they treat.

Alex M. Azar II, JD, discusses problems with the Affordable Care Act and the spread of misinformation surrounding drug costs during a session at the National Association of Specialty Pharmacy Annual Meeting and Educational Conference.

Sen Bill Cassidy, MD, spoke about the need for health care reform and the value of the specialty pharmacy at this year’s National Association of Specialty Pharmacy Annual Meeting and Educational Conference.

In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses the most common misconceptions that patients have about pain.

In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.

In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses how compounding pharmacists can help patients with chronic pain.

In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses the relationship between chronic pain and stress.

In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses why opioid abuse has become an increasingly urgent issue.

In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses the pharmacist's role in combating the opioid abuse epidemic.

In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses the challenges facing abuse-deterrent opioids as their manufacturers attempt to bring them to market.

In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses the mechanisms by which abuse-deterrent opioids prevent misuse.

In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses the benefits of abuse-deterrent opioids.

Patients who were treated by the IPT experienced a 61% greater reduction in morphine equivalent daily dose (MEDD) than those who received usual care group.

In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses treatment options for sleep-related pain.

Insurers can also help address this devastating epidemic.

In response to the growing opioid abuse epidemic, several health groups have written a petition requesting that the FDA remove ultra-high dosage unit (UHDU) analgesics from the market.

Pharmacists may soon be posed to take on new roles within the growing landscape of animal health.

There are several roles pharmacists can play in managing patients with cardiovascular disease, including blood pressure and medication monitoring.

The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of care.